Apollo Hospitals Demerger Nears Finish Line with Key Approvals

Introduction: Restructuring Plan Gains Momentum

Apollo Hospitals Enterprise Limited (AHEL) is moving closer to completing a significant corporate restructuring designed to unlock value in its pharmacy and digital health verticals. The company has secured crucial no-objection letters from both the National Stock Exchange (NSE) and BSE Limited for its composite scheme of arrangement. These approvals, following an earlier clearance from the Competition Commission of India (CCI), pave the way for the creation and eventual stock market listing of a new consolidated entity, Apollo Healthtech Limited (AHTL).

A Series of Regulatory Green Lights

The journey towards this demerger has been marked by several key regulatory milestones over the past year. The process began with the board's approval in June 2025, setting in motion a complex plan to streamline its operations. The first major external validation came from the Competition Commission of India, which approved the multi-layered transaction on September 24, 2025. The CCI's clearance confirmed that the proposed consolidation would not adversely affect market competition.

Following this, the plan was submitted to the stock exchanges for their review. The NSE issued its no-objection letter on December 23, 2025, under Regulation 37 of the SEBI (LODR) Regulations, 2015. BSE Limited provided a similar observation letter, stating it had no adverse observations on the scheme. These approvals are critical prerequisites that allow Apollo Hospitals to proceed with filing the scheme with the National Company Law Tribunal (NCLT) for final sanction.

Understanding the Composite Scheme

The restructuring is a multi-step process designed to consolidate Apollo's omnichannel pharmacy, distribution, and digital health businesses under a single umbrella. The plan involves several distinct corporate actions:

1. Demerger: An identified business undertaking from the parent company, Apollo Hospitals Enterprise Ltd (AHEL), will be demerged into Apollo Healthtech Ltd (AHTL).
2. Amalgamation: Two other entities, Apollo Healthco Limited (AHL) and Keimed Private Limited, will be merged into AHTL. AHL operates the Apollo 24|7 digital platform, while Keimed is a key player in wholesale pharmacy distribution.
3. Acquisition: AHTL will acquire a 74.5% stake in Apollo Medicals Pvt Ltd (AMPL) from its existing shareholders.

This consolidation will bring all related pharmacy and digital health assets into AHTL, creating a streamlined and powerful entity ready for an independent listing.

Strategic Vision and Financial Targets

The primary objective behind this complex restructuring is to unlock the intrinsic value of Apollo's fast-growing pharmacy and digital health businesses. By separating them from the mature hospital operations, the management aims to provide greater focus, attract dedicated investors, and achieve a more accurate market valuation for the new entity. This move allows existing AHEL shareholders to gain direct ownership in what is poised to become India's largest omnichannel pharmacy and digital health platform.

The management has set ambitious financial targets for the new entity. It is aiming for a revenue of ₹25,000 crore by the fiscal year 2027, a significant increase from the current revenue run rate of approximately ₹16,200 crore. The plan also targets an improvement in EBITDA margins to 7% by FY27, up from the current 3.5%.

The Path to Listing

With approvals from the CCI and stock exchanges secured, Apollo Hospitals is now preparing for the next and final phase of the regulatory process. The company will file the composite scheme with the NCLT for its consideration and approval. This stage also involves securing approvals from shareholders and creditors.

According to the company's CFO, Krishnan Akhileswaran, the entire process is expected to conclude by the last quarter of the 2026-27 fiscal year. The listing of Apollo Healthtech Limited's shares will follow shortly after the NCLT's final order, with trading expected to commence simultaneously on both the NSE and BSE.

Market Impact and Analysis

The creation of Apollo Healthtech Limited is set to have a significant impact on India's healthcare and pharmaceutical landscape. It establishes a formidable, integrated player that combines offline pharmacy distribution with a robust digital health platform. This omnichannel approach is well-positioned to capture a larger share of the growing healthcare market, driven by increased consumer health awareness and digital adoption.

For investors, the demerger provides a clear choice between investing in a stable, mature hospital business (AHEL) and a high-growth, technology-driven pharmacy and digital health platform (AHTL). This separation is expected to lead to better price discovery and potentially unlock significant shareholder value that may currently be submerged within the larger, consolidated AHEL structure.

Conclusion

Apollo Hospitals has methodically navigated the complex regulatory landscape to advance its strategic restructuring. With approvals from the CCI, BSE, and NSE now in hand, the plan to demerge and list its pharmacy and healthtech businesses has cleared its most significant hurdles. The company's focus now shifts to the NCLT process, with the final goal of listing Apollo Healthtech Limited by early 2027 and establishing it as a dominant force in India's omnichannel healthcare ecosystem.